FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002244985> ?p ?o ?g. }

• W2002244985 endingPage "839" @default.
• W2002244985 startingPage "825" @default.
• W2002244985 abstract "Though triptans are the most widely used acute treatments for migraine, response to treatment is sometimes suboptimal. Triptan therapy is often augmented by the addition of other acute treatments. The benefits of this practice have not been examined in large-scale, real-world observational studies.To assess changes in headache-related disability associated with adding additional acute treatments to a triptan regimen by category of added treatment including: a second triptan, nonsteroidal anti-inflammatory drugs (NSAID), opioids or barbiturates.Subjects were participants in the American Migraine Prevalence and Prevention study, a longitudinal, US population-based study of individuals with severe headache. Respondents who met International Classification of Headache Disorders 3 beta criteria for migraine were on triptan therapy per respondent self-report, used the same triptan, and provided headache-related disability data for at least 2 consecutive years. Subjects were divided based on headache days per month into 3 groups: low-frequency episodic migraine (LFEM, 0-4), moderate-frequency episodic migraine (MFEM, 5-9), and high-frequency episodic migraine/chronic migraine (HFEM/CM, ≥ 10 headache days per month). HFEM and CM were combined into a single group for analyses because of sample size limitations. Patterns of acute treatment for migraine were monitored from one year to the next over the following couplets of years (2005-2006, 2006-2007, 2007-2008, and 2008-2009). The first eligible couplet was analyzed for each respondent. Medication regimens studied included: (1) maintaining current triptan use (consistent group); (2) adding a different triptan; (3) adding an NSAID; or (4) adding a combination analgesic containing opioids or barbiturates. We assessed change in Migraine Disability Assessment (MIDAS) score from the first to the second year of a couplet, contrasting scores of participants with consistent use with those who added an acute treatment to their triptan regimen.The study sample (N = 2128) included 111 individuals who added another triptan, 118 who added an opioid or barbiturate, and 69 who added an NSAID, with referent groups of approximately 600 cases in each group who remained consistent. In general, MIDAS scores were higher among those who made changes from one year to the next compared with those who did not make changes in therapy. In fully adjusted models, adding triptans or NSAIDs was associated with increased disability for HFEM/CM cases at follow-up but decreased disability at follow-up for MFEM cases, resulting in significant interaction effects for both adding triptans and NSAIDs, respectively (15.88, 95% confidence interval [CI] 0.75, 31.01, 38.52, 95% CI 12.43, 64.61).While the effects of adding vs staying consistent on the outcome of headache-related disability varied by medication type added and headache frequency strata, in general, these results suggest that for individuals with migraine, adding acute therapies to current triptan use is generally not associated with reductions in headache-related disability. The results were strongest among persons with HFEM and CM. These results identify important unmet medical needs in current migraine management, especially among patients with high-frequency migraine, and suggest that alternative treatment strategies are needed to improve patient outcomes." @default.
• W2002244985 created "2016-06-24" @default.
• W2002244985 creator A5000448269 @default.
• W2002244985 creator A5015730759 @default.
• W2002244985 creator A5024044218 @default.
• W2002244985 creator A5033652829 @default.
• W2002244985 creator A5046836579 @default.
• W2002244985 creator A5063765693 @default.
• W2002244985 creator A5068648493 @default.
• W2002244985 date "2015-04-17" @default.
• W2002244985 modified "2023-10-05" @default.
• W2002244985 title "Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study" @default.
• W2002244985 cites W1931794981 @default.
• W2002244985 cites W1968865115 @default.
• W2002244985 cites W1980229633 @default.
• W2002244985 cites W1984102564 @default.
• W2002244985 cites W1992348398 @default.
• W2002244985 cites W1998171820 @default.
• W2002244985 cites W1999107496 @default.
• W2002244985 cites W2004272360 @default.
• W2002244985 cites W2024033337 @default.
• W2002244985 cites W2025275568 @default.
• W2002244985 cites W2030225029 @default.
• W2002244985 cites W2036913626 @default.
• W2002244985 cites W2038152559 @default.
• W2002244985 cites W2039359406 @default.
• W2002244985 cites W2041898141 @default.
• W2002244985 cites W2047455969 @default.
• W2002244985 cites W2065369272 @default.
• W2002244985 cites W2082473487 @default.
• W2002244985 cites W2084304739 @default.
• W2002244985 cites W2086126627 @default.
• W2002244985 cites W2089559518 @default.
• W2002244985 cites W2091270761 @default.
• W2002244985 cites W2093700658 @default.
• W2002244985 cites W2101513343 @default.
• W2002244985 cites W2105667364 @default.
• W2002244985 cites W2111548432 @default.
• W2002244985 cites W2116327175 @default.
• W2002244985 cites W2116941156 @default.
• W2002244985 cites W2118912931 @default.
• W2002244985 cites W2119392068 @default.
• W2002244985 cites W2132322340 @default.
• W2002244985 cites W2143103770 @default.
• W2002244985 cites W2148060026 @default.
• W2002244985 cites W2156931615 @default.
• W2002244985 cites W2166530830 @default.
• W2002244985 cites W2323511791 @default.
• W2002244985 cites W2769724041 @default.
• W2002244985 cites W4255396331 @default.
• W2002244985 doi "https://doi.org/10.1111/head.12556" @default.
• W2002244985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25881857" @default.
• W2002244985 hasPublicationYear "2015" @default.
• W2002244985 type Work @default.
• W2002244985 sameAs 2002244985 @default.
• W2002244985 citedByCount "20" @default.
• W2002244985 countsByYear W20022449852015 @default.
• W2002244985 countsByYear W20022449852016 @default.
• W2002244985 countsByYear W20022449852017 @default.
• W2002244985 countsByYear W20022449852018 @default.
• W2002244985 countsByYear W20022449852019 @default.
• W2002244985 countsByYear W20022449852020 @default.
• W2002244985 countsByYear W20022449852021 @default.
• W2002244985 countsByYear W20022449852022 @default.
• W2002244985 countsByYear W20022449852023 @default.
• W2002244985 crossrefType "journal-article" @default.
• W2002244985 hasAuthorship W2002244985A5000448269 @default.
• W2002244985 hasAuthorship W2002244985A5015730759 @default.
• W2002244985 hasAuthorship W2002244985A5024044218 @default.
• W2002244985 hasAuthorship W2002244985A5033652829 @default.
• W2002244985 hasAuthorship W2002244985A5046836579 @default.
• W2002244985 hasAuthorship W2002244985A5063765693 @default.
• W2002244985 hasAuthorship W2002244985A5068648493 @default.
• W2002244985 hasBestOaLocation W20022449851 @default.
• W2002244985 hasConcept C126322002 @default.
• W2002244985 hasConcept C1862650 @default.
• W2002244985 hasConcept C187212893 @default.
• W2002244985 hasConcept C2777119127 @default.
• W2002244985 hasConcept C2778541695 @default.
• W2002244985 hasConcept C2780564907 @default.
• W2002244985 hasConcept C2781413609 @default.
• W2002244985 hasConcept C2908647359 @default.
• W2002244985 hasConcept C2910587157 @default.
• W2002244985 hasConcept C42219234 @default.
• W2002244985 hasConcept C71924100 @default.
• W2002244985 hasConcept C99454951 @default.
• W2002244985 hasConceptScore W2002244985C126322002 @default.
• W2002244985 hasConceptScore W2002244985C1862650 @default.
• W2002244985 hasConceptScore W2002244985C187212893 @default.
• W2002244985 hasConceptScore W2002244985C2777119127 @default.
• W2002244985 hasConceptScore W2002244985C2778541695 @default.
• W2002244985 hasConceptScore W2002244985C2780564907 @default.
• W2002244985 hasConceptScore W2002244985C2781413609 @default.
• W2002244985 hasConceptScore W2002244985C2908647359 @default.
• W2002244985 hasConceptScore W2002244985C2910587157 @default.
• W2002244985 hasConceptScore W2002244985C42219234 @default.
• W2002244985 hasConceptScore W2002244985C71924100 @default.
• W2002244985 hasConceptScore W2002244985C99454951 @default.

• next